Author: Serkadis

TK Carsites releases Power SEO at the Digital Dealer Conference and helps auto dealers to generate leads ahead of their competition

ORANGE COUNTY, Calif., April 20 /CHICAGOPRESSRELEASE.COM/ — TK Carsites, the leader of internet marketing solutions and SEO for auto retailers, released Power SEO, combining new methodologies to bring you the finest SEO solution in the industry today.

Internet Marketing and Search Engine Optimization (SEO) in particular are rapidly developing technologies and TK Carsites is setting the direction for the industry with this release after already being the market leader. As recent as last November, TK Carsites received the Automotive Search Marketing Architecture (ASMA) “Super Charged Search” award as recognition of its leadership in SEO and Social Media.

TK Carsites CEO, Richard Valenta, commented, “Today’s release of TK Carsites’ Power SEO advances opportunities for auto dealers to generate more revenue from Internet Marketing, and provides you with a complete solution that, dollar for dollar, will deliver more ROI than any other advertising medium, period.” Power SEO combines multiple packages and new methodologies to bring you the finest SEO solutions in the industry today, allowing you to:

• Control Your Primary Market Area
• Get More Ups with Local Maps
• Dominate Your Competitors
• Take Business from Other Brands
• Manage Your On-Line Reputation

For more information, dealers can call 800-899-7791.

About TK Carsites, Inc.

TK Carsites, Inc. is an international marketing and technology services company specializing in providing solutions to automotive retailers. TK Carsites offers 1300+ auto dealer clients: high-converting websites, aggressive search engine optimization and social media marketing strategies along with numerous interactive and cutting-edge products.  www.tkcarsites.com  

SOURCE TK Carsites, Inc.

http://www.tkcarsites.com

Distributed via Chicago Press Release Services

Here it is, folks! Hot of the heels from the recent Captivate event in Hawaii comes a leaked trailer of Marvel vs. Capcom 3. Watch it after the jump before Capcom yanks it off the interwebs.
 

GENEVA, April 20 /CHICAGOPRESSRELEASE.COM/ — STMicroelectronics (NYSE: STM) has announced the main resolutions to be submitted for shareholder approval at the Company’s Annual General Meeting which will be held in Amsterdam on May 25, 2010.

The main resolutions, proposed by the Supervisory Board, include:

• Approval of the Company’s 2009 accounts reported in accordance with International Financial Reporting Standards (IFRS);
• The reappointment for a three-year term, expiring at the 2013 Annual General Meeting, for the following members of the Supervisory Board: Mr. Raymond Bingham and Mr. Alessandro Ovi;
• The distribution of a cash dividend of US$0.28 per share, to be paid in four equal quarterly installments, as further explained below.

The record date for all shareholders to participate at the Annual General Meeting will be April 28, 2010. The complete agenda and all relevant detailed information concerning the STMicroelectronics N.V. Annual General Meeting, as well as all related AGM materials, will be available on the Company’s web site (www.st.com) and made available to shareholders in compliance with legal requirements.

As indicated above, the resolution proposed by the Supervisory Board foresees the distribution of a cash dividend of US$0.28 per share, to be paid in four equal quarterly installments in June, August and December 2010 and February 2011 to shareholders of record in the month of each quarterly payment.

If approved, for the first installment, the Company’s common shares will trade ex-dividend on Euronext Paris and the Milan Stock Exchange (Borsa Italiana), on Monday, May 31, 2010, and the payment date will be Thursday, June 3, 2010. For holders of shares listed on the New York Stock Exchange, shares will trade ex-dividend on Friday, May 28, 2010, the record date will be Wednesday, June 2, 2010, and the payment date will be on or after Tuesday, June 8, 2010. Transfers between New York and European (Dutch) registered shares will be closed from the end of business in Europe on Friday, May 28, 2010, until the open of business in New York on Thursday, June 3, 2010.

The table below summarizes the full schedule for the four installments:

*Since the Annual General Meeting will be held on May 25, the Company will be unable to both set the ex-dividend date for, and to pay, the first dividend installment in May according to the usual schedule, and has therefore resolved, in coordination with the stock exchange and with a view to ensuring the appropriate functioning of the market for its shares from a substantive standpoint, to pay such installment on June 3 with an ex-dividend date on May 31 (May 28 in NY). Other than indicated below, the ex-dividend and payment dates for the subsequent installments are consistent with the usual schedule.

**May 31, 2010 and February 21, 2011 are not trading days on the New York Stock Exchange.

About STMicroelectronics

STMicroelectronics is a global leader serving customers across the spectrum of electronics applications with innovative semiconductor solutions. ST aims to be the undisputed leader in multimedia convergence and power applications leveraging its vast array of technologies, design expertise and combination of intellectual property portfolio, strategic partnerships and manufacturing strength. In 2009, the Company’s net revenues were $8.51 billion. Further information on ST can be found at www.st.com.

SOURCE STMicroelectronics

http://www.st.com

Distributed via Chicago Press Release Services

LIMASSOL, Cyprus, April 20 /CHICAGOPRESSRELEASE.COM/ — FxPro Financial Services Ltd (FxPro), one of the world’s most dynamic and fastest growing retail brokers in FX and CFDs, today announces its client services are now fully operational 24 hours a day, seven days a week.  In its latest initiative to provide an expanding and innovative service offering to its customers, FxPro launches a comprehensive set of services available around the clock to support clients during the complete lifecycle of their trading activity.

Since its launch in 2007, FxPro has been committed to providing an innovative and flexible service to its clients. Based upon ongoing client feedback, FxPro has worked to tailor its offering to ensure it meets the needs of the majority of its investors who often only have time to consider their investments in FX and CFDs and trade outside of the working day. FxPro has successfully been trialling a 24/7 service with clients since January 2010 and this has now become a permanent feature.

George Xydas, Director of International Operations, FxPro commented, “It is a major milestone for FxPro to offer the full suite of client support services on a 24/7 basis. This new service will allow us to help our traders with any account query or request and provide operational staff from Back Office and Administration, to Customer Support, Technical and Sales around the clock. FxPro’s objective is to provide industry leading, innovative customer service and this marks the latest evolution as we continue to strive to better serve our client needs.”

24/7 services will include Back Office (account opening and verification, and client changes to existing accounts); Accounting (deposits and withdrawals and use of all payment methods), Customer Support (platform, trading and general enquiries, via Live Chat, Freephone, Dial-Back and Email), and Sales (support for new accounts registration, as well to help with newly registered clients). All clients have the opportunity to live chat or email in order to access the information they need 24 hours a day, seven days a week.

In a recent client survey we asked:

Are you more happy with the services, now that they are available 24/7 and what is it specifically that you like about our 24/7 customer service?

“Yes very much, in fact that’s one of the reasons I am using FxPro.”

Mr. Emenike Collins

“24/7 is all the more better as people like me typically find weekends for doing such extra work, so it is definitely convenient and I appreciate it.”

Mr. Yogender Gupta

“Everything, especially the one on one contact with the members of staff, the quick response I get whenever I want to chat.”

Mr Christopher Aggo

“I really really appreciate that you are there for us all the time. Thanks for the better service.”

Mrs Lan-nie Chen

Notes to Media

About FxPro

FxPro Financial Services Ltd (FxPro) is one of the world’s most dynamic and fastest growing retail foreign exchange (Forex) brokers.  Operating since 2007, our innovative management approach produces a successful growth business among peers benefiting from strong global diversification serving clients residing in 120 countries with industry-leading technology and unmatched, 24/7 live customer support. We are a Cyprus Securities and Exchange Commission authorized and regulated financial services company (license no. 078/07), and operate under the EU Markets in Financial Instruments Directive (MiFID).  FxPro is the  Official Forex Trading Partner of Virgin Racing’s Formula One Team and the FIA World Rally Championship, and is well on its way to becoming the world’s preferred Forex broker.  For further information, please visit www.FxPro.com.

SOURCE FxPro

http://www.fxpro.co.uk

Distributed via Chicago Press Release Services

A development team from Indiana and New York wants to build a 158-unit apartment complex on Rockford’s south side near the intersection of 11th Street and Sandy Hollow Road, but the city says the proposal conflicts with long-range plans.

LandWhite Developers LLC has put together a $17.6 million proposal to build the rental units, called The Village of Southgate, and improve the parking lot and facade of the shopping center just north of where it wants to build six apartment buildings. The team wants to obtain $12.2 million from the U.S. Department of Housing and Urban Development and $4.6 million from state housing tax credits. It plans to spend $800,000 of its own money, said LandWhite partner David Roos, and has an option on 6.9 acres where it intends to build.

Roos and his partners plan to take their proposal to the city’s Zoning Board of Appeals tonight despite a thumbs-down recommendation from city staff.

“We have a strong market study that came back very positive. We’ve got commitments from some of our lenders. The missing link is the (city’s approval of a planned unit development application),” Roos said Monday. “We’ve had positive conversations with the city, and we believe we’ve addressed their concerns.”
Not appropriate land use
Todd Cagnoni, deputy director of Rockford’s Community and Economic Development Department, said the city’s denial remains based on the proposal’s inconsistency with its land use plan.

“It’s not that these developers haven’t made an effort to appropriately design their development,” Cagnoni said. “The fundamental concern of staff is that it’s not the appropriate land use. It’s not consistent with our 2020 plan, nor is it consistent with the TIF plan that we’ve adopted for that area. We’re looking for more commercial and industrial uses to go in that area rather than residential.”

Going against the city’s plan can cause problems down the road, Cagnoni added.

“Once you start going against the land use plan, you start taking opportunities away from commercial development that you’d like to see in the future, and you’re setting the stage that it’s going to be a residential development and we’re going to have to provide the services that we typically provide for residential, which is not planned for that particular area.”

But Roos argued that the current zoning classification would allow for a residential development. He said he’s asking the zoning board for height and setback variances.

Rents of $630 to $930
The one- to three-bedroom units would rent for $630 to $930 a month, Roos said, and the development would bring hundreds of construction jobs to the area.

Because of the types of funding that LandWhite hopes to obtain, The Village would need to rent 80 percent of its units to people who meet income eligibility requirements, Roos said. The remaining 20 percent would be market rate, he said.

LandWhite also is putting together a proposal for the redevelopment of Church School on Rockford’s west side.

Staff writer Corina Curry can be reached at [email protected] or 815-987-1371.

Read the original article from the Rockford Register Star.

Distributed via Chicago Press Release Services

ST. LOUIS, April 20 /CHICAGOPRESSRELEASE.COM/ — Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich® (Nasdaq: SIAL), today announced an extension to its award-winning CompoZr® product offering with the global release of the CompoZr Targeted Integration Kit, AAVS1 (www.sigma.com/aavs1).  This kit provides a powerful method for the controlled transgene integration and expression of any gene in any human cell line using Sigma-Aldrich’s proprietary CompoZr Zinc Finger Nuclease (ZFN) technology.

Specifically, the CompoZr Targeted Integration Kit enables users to rapidly integrate their gene of interest into a single locus on human chromosome 19, from where it will be expressed in a stable manner. Unlike other methods for transgene expression in human cells, this kit enables users to study their gene in the cell line of their choice, providing stable, uniform protein expression while eliminating the need to engineer cell lines with transgene landing pads.

“Our new Targeted Integration Kit provides a valuable tool for scientists working with all types of human cells, including stem cells,” said Patrick Sullivan, vice president of Research and Development for Sigma-Aldrich’s Research Biotech business unit.  ”Similar to what the Rosa26 locus has done for transgenic research in mice, we believe the AAVS1 locus will provide a ’safe harbor’ site from which to study gene function and expression.  The kit, using Zinc Finger Nuclease technology, enables researchers to insert any gene construct into the human genome. This new kit is an exciting addition to our offering of CompoZr products, and will facilitate the construction of isogenic cells with permanent, stable gene expression.”

The CompoZr Targeted Integration Kit offers a number of benefits over current methods of transgene expression in human cells. Traditional use of random insertion to introduce a DNA construct into the human genome may lead to gene disruption, variable epigenetic effects on transgene expression and presence of an unknown number of integrants in each cell, making comparisons difficult between isolated single cell clones. The CompoZr Targeted Integration Kit uses a ZFN to target the transgene specifically into the AAVS1 locus in the human genome leading to mono- or bi-allelic insertions enabling the stable expression and study of transgenes in cell lines where the number of integrants and the locus of integration is controlled by the researcher.  

More information on Sigma-Aldrich’s CompoZr ZFN technology platform can be accessed by visiting www.compozrzfn.com, part of the recently-launched ‘Where Bio Begins’ brand and website (www.wherebiobegins.com).  ’Where Bio Begins’ is a leading digital destination where the biological research community can directly access the deep biological knowledge they require for their research, while driving awareness of Sigma-Aldrich’s strengths in providing products and technologies that facilitate scientists’ understanding of how diseases develop and how molecules function.

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as “provides a valuable tool,” “will provide a safe harbor site,” “enables researchers,” “offers a number of benefits” or similar expressions, or by express or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the CompoZr Targeted Integration Kit will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of the CompoZr Targeted Integration Kit will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding the CompoZr Targeted Integration Kit could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company’s assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich’s current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma’s leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

CompoZr, Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

http://www.sigma-aldrich.com

Distributed via Chicago Press Release Services

Article Tags: Headline Story, Piers Corbyn

Click to download PDF file to read FULL report from Piers Corbyn

Read in full with comments »   

SINGAPORE, April 20 /CHICAGOPRESSRELEASE.COM/ — Over the next five years, technological advancements in therapeutics are expected to amplify the number of patients diagnosed with systemic fungal infection (SFI) in Thailand. The significant increase in number of patients is shifting the focus of managing SFI from empiric and prophylactic methods to targeted and pre-emptive treatment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), Systemic Fungal Infection Therapeutics Market – Thailand, estimates that the global prevalence of SFI has risen to four for every one thousand of the global population. Similarly, the incidence of SFI has increased steadily over the years due to the widespread use of broad-spectrum antibiotics, which reduce non-pathogenic bacterial population that compete with fungi, and the increased number of persons with compromised immune systems caused by AIDS, immunosuppressant drugs, and chemotherapy agents.

The SFI therapeutics market is also likely to receive a shot in the arm with a high premium on products that are capable of tackling emergent, problematic pathogens. As more resistant pathogens in SFI emerge, therapy will revolve around ensuring that the right treatment is administered. This is made possible through non-microbiologic and clinical diagnostic techniques (Platelia, Fungitell, and PNA FISH®) to identify the onset of infection.

Although there are key therapeutics to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Doctors are under increasing pressure to ensure that they choose the right course of treatment the first time, based on the universal criteria of risk factors, clinical, radiological, microbiological, or other diagnostic evidence.

“This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices,” says Frost & Sullivan Program Manager Carole Gaffud. “As a result, there would be a reduction in the use of prophylaxis in the ‘at risk’ patient group, and empiric therapy in patients groups with a persistent fever or other suggestive symptoms.”

Given the relatively niche nature of SFI, it is important for key participants to differentiate their products, especially as advancements in diagnostic techniques restrict prescriptions to specific therapeutic uses. As therapeutics shift from broad and empiric indications, pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and subspecies) and patient population. This enables greater differentiation, thereby protecting the specific drug from generic erosion in the future.

“The changing epidemiology of causative pathogens has caused a decline in the effectiveness of existing therapeutic options,” notes Gaffud. “Pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups (solid organ transplant patients, cancer patients, neonates, HIV/AIDS patients, and surgery patients).”

If you are interested in more information on this study, please send an e-mail to Nicklaus Au, Corporate Communications, at [email protected] and [email protected] with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

Systemic Fungal Infection Therapeutics Market – Thailand is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: The Systemic Fungal Infection Therapeutics Market in Hong Kong, The Systemic Fungal Infection Therapeutics Market in China, The Systemic Fungal Infection Therapeutics Market in Australia, The Systemic Fungal Infection Therapeutics Market in Singapore, The Systemic Fungal Infection Therapeutics Market in India, The Systemic Fungal Infection Therapeutics Market in Taiwan, The Systemic Fungal Infection Therapeutics Market in Malaysia, The Systemic Fungal Infection Therapeutics Market in the Philippines, and The Systemic Fungal Infection Therapeutics Market in South Korea. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

SOURCE Frost & Sullivan

http://www.frost.com

Distributed via Chicago Press Release Services

HOUSTON, April 20 /CHICAGOPRESSRELEASE.COM/ — As incoming college freshmen prepare to turn in their acceptance letters on May 1, many families are scrambling to figure out how to fund their teens’ education. Nearly one-in-two (45 percent) Houston-area teens surveyed indicated they had changed their college plans because of the economy. This is among the key findings in the Houston-area administered 2010 Junior Achievement/Allstate Foundation “Teens and Personal Finance” Survey.

Included within the 45 percent whose college plans have changed, 16 percent are working more to pay for college, 14 percent are staying closer to home or are not attending college out of state, 9 percent plan on going to a community college, 4 percent may delay school for one year or longer and 2 percent are not planning to go to college.

Economic pressures and steadily increasing tuition are forcing teens and their families to exercise financial discipline to pay college costs. A majority of Houston-area teens—55 percent—report they and their families are saving for college, with 20 percent of those teens saving their own money and 35 percent reporting their parents are saving for their college educations. However, nearly one-in-five (17 percent) haven’t determined how they will pay for college.

Interestingly, 44 percent of Houston-area teens say they plan on getting college scholarships. Yet, 66 percent of all U.S. undergraduates received some type of financial aid in 2007–08, including grants, loans and scholarships, according to the U.S. Department of Education. Those who miss out on financial aid opportunities will be left with tough financial decisions to make.

Of those students nationwide who do receive some type of financial aid, U.S. Department of Education data show that the median amount of student-loan debt carried by 2007-08 bachelor’s degree recipients at public four-year colleges was $17,700 and $22,375 at private four-year institutions.

This debt level has taken its toll on students’ ability to repay their loans, as evidenced in the rise of student-loan default rates. The latest data from the U.S. Department of Education show that default rates are up from 5.2 percent in 2006 to 6.7 percent in 2007.

Considering that nearly seven percent of college graduates across the country default on their student loans, it is imperative that teens weigh their ability to service their student loans when making college and career choices—equally important are solid financial planning.

“Junior Achievement aims to provide students with a strong set of money-management skills, so they can effectively budget, use credit, and save,” noted Rick Franke, president of Junior Achievement of Southeast Texas. “Since April is Financial Literacy Month, it is a great time to reinforce the importance of those skills.”

Junior Achievement and The Allstate Foundation have partnered to create Junior Achievement, $ave USA, a financial literacy initiative comprised of free, downloadable money management exercises for parents and their children to do together.

For a full survey abstract, contact Kevin R. Hattery at [email protected].

SOURCE Junior Achievement of Southeast Texas

http://houston.ja.org

Distributed via Chicago Press Release Services

Rocksteady has already made the promise that Batman: Arkham Asylum 2 won’t let anyone down. Now, Batman’s voice actor, Kevin Conroy, reveals that it will be “really, really dark.”
 
 
 
 

Global Sources is also launching new Made in India show in Dubai this June to meet rising demand in the Middle East for products from India

HONG KONG, April 20 /CHICAGOPRESSRELEASE.COM/ — Global Sources’ ( GSOL)
largest-ever India Sourcing Fair: Home Products (http://www.india-
sourcingfair.com ) opened today at AsiaWorld-Expo in Hong Kong and runs until
April 23.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030303/LNM011LOGO-b )

The Fair offers international buyers more than 110 booths of India
suppliers displaying their latest handicrafts, kitchenware, glassware and
metalware, home decor, home textiles, jute and paper products.

Reflecting the increasing demand for products from India, the spring 2010
show has 10 percent more booths than Global Sources’ debut India Sourcing
Fair: Home Products held in Hong Kong in April 2009.

“The show’s expansion this year provides suppliers from India with greater
sales opportunity and exposure,” said Tommy Wong, President of Global Sources
Exhibitions. “Thousands of buyers are drawn to this Fair, as it is a
world-class exhibition for unique products from quality India suppliers — all
in the convenience of Hong Kong.

“India’s exports in February surged by 34.8 percent year-on-year to $16.1
billion. That follows growth of 11.5 percent in January this year and 9.3
percent last December. With demand for India’s exports around the world
rebounding, this is clearly the time for India suppliers to exhibit at the
Fair and meet face-to-face with buyers.”

India suppliers and export federation embrace opportunities Fair offers

Exhibitors are responding well to the Hong Kong show. Mohammed Adil
Shamsi, Managing Director of Giftmark Industries, said: “The India Sourcing
Fair is a great chance for us to secure more orders. That is a vital sales
channel for us to benefit from the rebound in global demand.”

The Federation of Indian Export Organisations (FIEO) supports Global
Sources’ India Sourcing Fair. The FIEO is the apex body of all Indian
export-promotion organizations, and the Indian government’s partner in
promoting the country’s international business.

O. P. Garg, FIEO committee member, will address buyers at the show’s
“Made-in-India: A market snapshot” seminar. The seminar provides insight
valuable in helping buyers source more effectively from suppliers in India. It
is scheduled for April 20 from 4:30 to 5:30 p.m. in room 201B of
AsiaWorld-Expo.

Made in India show set for June launch in Dubai

The Hong Kong event also sets the stage for the new Made in India — India
Sourcing Fair scheduled for June 8-10 in Dubai. This event is expected to be
the first-ever exhibition of quality Indian products in the United Arab
Emirates. India exporters have already booked 250 booths at the Dubai show.

Wong said: “We are taking Indian suppliers to the world’s top sourcing
centers, particularly Hong Kong and Dubai, to give them access to leading
international buyers. As the economic recovery strengthens, it is important
for Indian suppliers to reconnect with current buyers and seek new markets.”

For more information on India Sourcing Fair, visit
http://www.india-sourcingfair.com .

About Global Sources

Global Sources is a leading business-to-business media company and a
primary facilitator of trade with Greater China. The core business uses
English-language media to facilitate trade from Greater China to the world.
The other business segment utilizes Chinese-language media to enable companies
to sell to, and within Greater China.

The company provides sourcing information to volume buyers and integrated
marketing services to suppliers. It helps a community of over 888,000 active
buyers source more profitably from complex overseas supply markets. With the
goal of providing the most effective ways possible to advertise, market and
sell, Global Sources enables suppliers to sell to hard-to-reach buyers in over
240 countries.

The company offers the most extensive range of media and export marketing
services in the industries it serves. It delivers information on 4.5 million
products and more than 253,000 suppliers annually through 14 online
marketplaces, 13 monthly magazines, over 80 sourcing research reports and 17
specialized trade shows which run 55 times a year across 10 cities.

Suppliers receive more than 136 million sales leads annually from buyers
through Global Sources Online (http://www.globalsources.com ) alone.

Global Sources has been facilitating global trade for 39 years. Global
Sources’ network covers more than 60 cities worldwide. In mainland China,
Global Sources has about 2,500 team members in more than 40 locations, and a
community of over 1 million registered online users and magazine readers for
its Chinese-language media.

    Global Sources Press Contact in Asia:
     Camellia So
     Tel:   +852-2555-5021
     Email: [email protected]

    Global Sources Press Contact in U.S.:
     James W.W. Strachan
     Tel:   +1-480-664-8309
     Email: [email protected]

    Global Sources Investor Contact in Asia:
     Investor Relations Department
     Tel:   +852-2555-4777
     Email: [email protected]

    Global Sources Investor Contact in U.S.:
     Kirsten Chapman & Timothy Dien
     Lippert/Heilshorn & Associates, Inc.
     Tel:   +1-415-433-3777
     Email: [email protected]

SOURCE Global Sources

http://www.globalsources.comhttp://www.india-sourcingfair.com

Distributed via Chicago Press Release Services

A recent study reported that 6.8 percent of URLs accessed by businesses lead to Facebook and 10 percent of bandwidth goes to YouTube. Of course, as to be expected, along with such a study come the fears that security and worker productivity is harmed by allowing access to such “non-work” sites:

The figures show that IT managers are right to be concerned about the amount of social network use at work. There are two real concerns here: firstly that employees will be downloading applications from social networks and putting security at risk; and secondly the amount of corporate bandwidth that appears to be being used for non-corporate activity.

These fears seem to resurface every once in awhile, especially when some new technology starts to become ubiquitous in the workplace. First, it’s silly to think that social networks would somehow have more security-risking applications to download than the rest of the internet. As for the productivity concern, if you’re worrying about how much time your employees are spending doing “non-work” things, then you’re worrying about the wrong thing. From online shopping to social networking, allowing employees to do “non-work” web surfing while they are at the office keeps them happier and more productive. In fact, multiple studies have shown that social media sites like Twitter and Facebook actually make workers more productive by sparking creative ideas.

Of course, in order to manage this properly, managers must monitor productivity based on concrete, measurable goals — rather than focus on the time spent doing the work. After all, if you’re delivering results, why should your manager care if you spend a few minutes a day catching up with friends on Facebook?

Permalink | Comments | Email This Story

LEUVEN, Belgium, April 20, 2010 /CHICAGOPRESSRELEASE.COM/ –

– Highly Significant Trial Result (p=0.003) Demonstrates the Potential of
Microplasmin in the Treatment of Retinal Disease

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company
focused on the discovery and development of innovative treatments for eye
disease, vascular disease and cancer, announces that its first Phase III
trial with microplasmin for the non-surgical treatment of eye disease has met
its primary endpoint (p=0.003). The trial, TG-MV-006, recruited a total of
326 patients in the U.S. A second Phase III study with microplasmin,
TG-MV-007, which recruited a similar number of patients in the U.S. and
Europe, is due to report in the third quarter of 2010.

The microplasmin Phase III program, referred to as MIVI-TRUST
(Microplasmin for IntraVitreous Injection-Traction Release without Surgical
Treatment), consists of two multi-center, randomized, placebo controlled,
double-masked trials. These trials are designed to evaluate 125μg of
microplasmin versus placebo in the intravitreal treatment of patients with
symptomatic focal vitreomacular adhesion (VMA). The MIVI-TRUST program is the
largest interventional clinical program ever performed to specifically
evaluate the vitreoretinal interface in patients with retinal disorders.

The primary endpoint of both trials is the non-surgical resolution of
focal vitreomacular adhesion one month after a single injection of
microplasmin. This endpoint is being measured and recorded using optical
coherence tomography (OCT), the standard method of assessment for this
condition, which provides images that can clearly show the separation of the
vitreous from the retina.

The results of the first trial, TG-MV-006, confirmed that it had met its
primary endpoint with 27.7% of microplasmin treated patients achieving
resolution of their VMA compared to 13.2% of patients treated with placebo
injection (p=0.003). A Per Protocol analysis of the microplasmin treated
patient population showed that 30.7% achieved resolution of their VMA
(p=0.004).

In addition to the primary endpoint, the Phase III trials will evaluate
additional measures of efficacy as well as safety, assessed at various time
periods over the six month study period. These data will be presented at the
World Ophthalmology Congress (WOC) in Berlin by Dr. Matthew Benz, MD (Baylor
College of Medicine, Houston, Texas, U.S.).

Dr. Patrik De Haes, CEO of ThromboGenics, commented, “This is the most
important milestone in ThromboGenics’ history. Microplasmin is key to the
success of our ophthalmic focused strategy, and we are very pleased to be
able to announce these positive results. The fact that microplasmin resolved
VMA without surgery in approximately 30% of patients is a clinically
important development. These results reaffirm our confidence in the potential
of this innovative approach to the treatment of a range of retinal disorders.
We are moving ahead with our pre-commercialization activities for
microplasmin, so that we are well-positioned to launch this unique product
successfully.”

About Focal Vitreomacular Adhesion (VMA)

Focal vitreomacular adhesion is a condition in which the vitreous gel, in
the center of the eye, has an abnormally strong adhesion to the macula, the
center of the retina at the back of the eye. Vitreomacular adhesion is
thought to play a key role in numerous back of the eye conditions, such as
macular hole and some forms of macular edema. Vitreomacular adhesion is also
associated with a poorer prognosis in certain major eye conditions, including
Diabetic Retinopathy and Age-related Macular Degeneration (AMD).

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and
development of innovative medicines for the treatment of eye disease,
vascular disease and cancer. The Company’s lead product microplasmin has
completed its first Phase III clinical trial for the non-surgical treatment
of back of the eye diseases. Microplasmin is also being evaluated in Phase II
clinical development for additional vitreoretinal conditions. In addition,
ThromboGenics is developing novel antibody therapeutics in collaboration with
BioInvent International; these include TB-402 (anti-Factor VIII), a long
acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase I for
cancer.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed
on Eurolist by Euronext Brussels under the symbol THR. More information is
available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered
“forward-looking”. Such forward-looking statements are based on current
expectations, and, accordingly, entail and are influenced by various risks
and uncertainties. The Company therefore cannot provide any assurance that
such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the business and
other factors that could cause actual results to differ materially from any
forward-looking statement is contained in the Company’s Annual Report.

    For further information please contact:

    ThromboGenic
    Dr. Steve Pakola, CMO                     Tel: +1(212)201-0920
                                              [email protected]

    Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                              [email protected]

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71
                                              [email protected]

SOURCE ThromboGenics NV

Distributed via Chicago Press Release Services

Here is the latest version of blabla’s homebrew project, Pokemon Battle, a homebrew RPG game for the Nintendo DS based on the popular anime series. The latest update of the homebrew has added some new features, more

A sport utility vehicle full of people headed for a funeral rolled over Sunday morning on Interstate 55, leaving one person dead and sending seven to the hospital.

The SUV was headed south about 10:45 a.m. on I-55 just north of McLean when the right rear tire came off and the driver lost control. The front seat passenger, a 61-year-old Wisconsin woman, was thrown from the SUV and was pronounced dead on the scene, McLean County Coroner Beth C. Kimmerling said in a news release.

The woman’s name has not been released. It was not known whether she was wearing a seat belt.

The SUV was the last vehicle in a three-vehicle group that was traveling from Rockford to St. Louis for a funeral. Seven other passengers were taken to Advocate BroMenn Medical Center in Normal.

Read the original article from Journal Star.

Distributed via Chicago Press Release Services

Two of the World’s Most Anticipated Motorbikes Will Make Their Debut on May 8, 2010 at Quail Lodge Golf Club in Carmel, Calif.

CARMEL, Calif., April 20 /CHICAGOPRESSRELEASE.COM/ — The Quail Motorcycle Gathering (www.quaillodgeevents.com) today announced that the technologically-advanced four-in-one Ducati Multistrada 1200 and the custom Kestrel Falcon will be unveiled at the Quail Motorcycle Gathering on Saturday, May 8 to be held at Quail Lodge Golf Club in Carmel, Calif.

“We are honored that Ducati and Falcon Motorcycles, the most distinguished companies in the industry, have chosen to debut their newest masterpieces at The Quail,” said Courtney Porras, Director of Special Events for Quail Lodge Golf Club. “Our guests will be among the first to have the unmatched opportunity to compare the aesthetics and engineering of these rare bikes.”

Ducati will be debuting its first production spec of the Ducati Multistrada 1200, the most technologically advanced motorcycle on the market.  The Multistrada has the ability to change from Sport, Touring, Urban and Enduro to accommodate every rider’s needs via four pre-set programs.  The groundbreaking bike combines innovative design, customized suspension and traction control with a 150 hp Testastretta 11 degree engine.

Equally impressive, Falcon Motorcycles, acclaimed for their meticulous custom creations, will introduce its follow up to the “Bullet Falcon”, The Kestrel, created around a 1970 Triumph Bonneville engine that Falcon’s Ian Barry cut in half and re-engineered. The one-of-a-kind motorcycle underwent more than 2,000 hours of radical design and fabrication work. Except for 10 inches of the original Triumph frame-neck, the entire frame, front forks, gas and oil tanks, exhausts, handlebars, levers – in fact every part of the motorcycle including the cylinders, were made 100 percent from scratch, in-house at the Falcon Motorcycles Los Angeles workshop.  The Kestrel is the second creation in Falcon’s Concept Ten, a collection of very different one-off bikes designed and fabricated around the engines of rare pre and post-war British motorcycles. The first is the acclaimed “Bullet Falcon,” which has come to be recognized as one of the most iconic two-wheelers in recent motorcycle history.  

Additional key motorcycles on display, amongst many others include a 1974 Ducati 750 SS, the last new bike of its kind sold in the United States; 1949 Vincent Black Lighting, one of only 30 motorcycles ever built and a 1937 Harley-Davidson 61ci Overhead valve V-Twin, also known as the “Knucklehead,” one of the most handsome and readily recognizable motorcycles of all time. The Quail has also added a 1975-1977 Honda GL 1000 feature display.  

Other highlights include the all new Honda VFR1200F, featuring the world’s first dual clutch transmission; Ducati test-rides; an Adam Wright photography exhibit; therapeutic chair massages; live entertainment and a delicious Southern flavor barbeque lunch highlighting The Monterey Peninsula region’s best local ingredients. Attendees will have access to the Bonhams & Butterfields’ auction of rare motorcycles and memorabilia which includes a beautifully restored 1957 Mondial 125cc Grand Prix dohc ‘Dustbin’, a rare 1910 Royal Pioneer 30.50ci Single, and a collection of four Vincent Prototypes built for Vincent’s reincarnation.

To kick-off The Quail Motorcycle Gathering, enthusiasts are invited to participate in a one-day Motorcycle Tour on Friday, May 7, 2010.  The scenic tour, limited to 50 participants, will wind through 100 miles of the Monterey Peninsula coastline, and will finish the day with an exclusive dinner. The cost to participate is $250 per person, which will include a gift bag, lunch, track time at the legendary Mazda Raceway Laguna Seca (where you can experience the “corkscrew” first hand,) and entrance into the evening reception, featuring special guest speakers and a preview of the Bonhams & Butterfields Auction Motorcycles.  

About the Quail Motorcycle Gathering

Tickets to The Motorcycle Gathering are $65 per person, $10 for children 12 and under, and inclusive of lunch, musical entertainment and access to the Bonhams & Butterfields auction. Quail is proud to be partnering with Riders for Health as the official event charity (www.riders.org). For more information call 877-734-4628 or visit www.quaillodgeevents.com. Tickets are on sale now, and can be purchased online at www.quaillodgetickets.com. A limited number of entrants and event sponsorships are still available. For more information please call (877) 734-4628.

SOURCE Quail Lodge Golf Club

http://www.quaillodgeevents.com

Distributed via Chicago Press Release Services

Former EMC Executive to Scale Sales Organization and Accelerate Growth

CAMBRIDGE, Mass., April 20 /CHICAGOPRESSRELEASE.COM/ — Brightcove, the leading online video platform, today announced that Paul Goetz has joined the company’s executive team as senior vice president of sales for North America. Goetz brings a wealth of management, sales and strategic experience to Brightcove from his successful 19-year tenure at EMC Corporation and most recently at SAVVIS, where he was responsible for the company’s sales and consulting group. At Brightcove, Goetz will help scale the company’s sales organization and drive customer acquisition activities across North America.

“Brightcove is experiencing tremendous demand for our online video platform, so we are very happy to have Paul join the team to ramp our sales organization and accelerate growth across our customer base in North America,” said David Mendels, Brightcove president and chief operating officer. “Paul brings a wealth of experience to the table, as well as a proven ability to deliver substantial revenue growth and drive results for some of the biggest brands in the world. I look forward to his contributions to the Brightcove team in the year ahead.”  

Paul Goetz brings more than 20 years of technology sales experience, most recently serving as senior vice president of U.S. sales and consulting at SAVVIS Corporation, where he led engagements with major consumer brands, media organizations and software-as-a-service (SaaS) providers. Prior to SAVVIS, Goetz spent 19 years at EMC Corporation, where he served as vice president of global consulting and managed services and was responsible for worldwide advanced services sales. In this role, Goetz worked with many of EMC’s top clients, built a highly productive global sales force, and led the design of the services sales model for the company. Early in his career, Goetz quickly rose through the ranks at EMC, moving up through sales management, to leading sales for Switzerland, Portugal, Spain and Italy, and later serving as vice president for solutions and services marketing for the company.

“I am very excited to join the Brightcove team given the company’s tremendous momentum and leadership position in the online video market,” said Goetz. “I have focused my entire career around client-facing leadership roles because I am passionate about solution selling and client relationships. I look forward to leveraging my experience and immediately contributing to the successful executive and sales team Brightcove already has in place.”

Goetz joins the Brightcove executive management team reporting to David Mendels.

About Brightcove

Brightcove is a cloud-based online video platform. Media companies, businesses and organizations worldwide use Brightcove to publish and distribute video on the Web. Founded in 2004, Brightcove has offices across North America, Europe and Asia and customers in 42 countries. For more information, visit http://www.brightcove.com.

SOURCE Brightcove

http://www.brightcove.com

Distributed via Chicago Press Release Services

Express Scripts First to Quantify Hidden Pharmaceutical Cost of Common Behaviors

ST. LOUIS, April 20 /CHICAGOPRESSRELEASE.COM/ — Express Scripts is the first organization ever to quantify the hidden healthcare costs of very common behaviors related to prescription drugs, such as forgetfulness and procrastination, estimating the annual wasteful spending at $163 billion.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080827/EXPRESSSCRIPTSLOGO)

The Express Scripts 2009 Drug Trend Report, released today, quantifies changes in drug spend on a year-to-year basis and details the costly effects of irrational behaviors on pharmacy-related costs. Express Scripts, one of the nation’s largest pharmacy benefit managers, has produced the Drug Trend Report for each of the past 14 years.

The Express Scripts 2009 Drug Trend Report creates a set of personas, such as Robert the Loyalist, to illustrate common behaviors that contribute to the billions we waste each year. Express Scripts is the first company to apply behavioral science to address healthcare challenges that individuals, policymakers and employers have faced for years.

“The good news is that these potential savings in the pharmacy benefit are tied to one of the few variables in healthcare we can readily influence: behavior,” said Steven Miller, MD, senior vice president and chief medical officer at Express Scripts. “This research shows that in terms of achieving lower costs and improved outcomes, healthcare reform starts in the home.”

Miller added, “If we optimized every individual’s behavior relating to prescription drugs, we could achieve savings that in five years would cover the projected costs of the recently passed national healthcare reform legislation.”

The $163 billion in wasteful spending results from three key factors:

• $106 billion from medical costs of non-adherence to therapy.
• $51 billion in missed opportunities related to lower-cost medication alternatives, both brand and generic.
• $6 billion in missed opportunities related to lower-cost options for delivery of medications.

The 2009 Drug Trend Report is the first to link spending to both market forces and behavioral factors. Overall, the drug spend for the United States increased 6.4 percent in 2009, reversing a pattern of lower drug trend increases in previous years, the report says. Market forces drove trend up by 8.3 percent, while behavior drove down trend by nearly 2 percent.

For example, within traditional prescription drugs, Express Scripts clients saved $1.4 billion through the increased use of generics and lower-cost brands. More than of half that savings, $790 million, came from Express Scripts’ behavior-centric programs in partnership with clients. Those savings were over and above some market factors that also helped hold down spending, such as the expiration of branded patents, which allows development of lower-cost generic drugs.

Through the lens of behavior, Express Scripts also has broken down the behavior-related waste by therapy class. For example, more than one-third of the annual spend (35.5 percent) on high cholesterol medication could be saved with better behavior.

Bob Nease, chief scientist at Express Scripts, said, “We have good cause for optimism that the behaviors causing this vast waste in healthcare can change. Express Scripts’ advanced application of behavioral science to healthcare, which we call Consumerology, has proved very successful in achieving behavior changes through programs that are fully voluntary.”

Other notable trends found in the Drug Trend Report include that diabetes is the top driver of total cost increases in the traditional drug sector because of growth in utilization and cost per prescription. Spending for drugs used to treat viral infections increased by approximately 25 percent primarily because of increased prevalence of use for agents used to treat influenza.

The full report is available for download at www.express-scripts.com

About Express Scripts

Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, is leading the way toward creating better health and value for patients through Consumerology®, the advanced application of the behavioral sciences to healthcare. This approach is helping millions of members realize greater healthcare outcomes and lowering cost by assisting in influencing their behavior. Headquartered in St. Louis, Express Scripts provides integrated PBM services including network-pharmacy claims processing, home delivery services, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. More information can be found at http://www.express-scripts.com and http://www.consumerology.com/ .

SOURCE Express Scripts

http://www.express-scripts.com

Distributed via Chicago Press Release Services

Filed under: Technology, Ford, Lincoln

On our way to Stanford last week, we came across a murdered-out Toyota Prius with an “I♥OPEC” vanity plate. Prime Twitter fodder if we’ve ever seen it. Unfortunately, even with our smartphone streaming navigation directions and a podcast through the Ford Fusion’s SYNC system, we couldn’t safely tweet our find. Well, Ford’s about to rectify that issue with the introduction of AppLink, a downloadable upgrade to the SYNC infotainment system that allows drivers to control their smartphone apps through voice commands.

AppLink will be exclusive to the 2011 Ford Fiesta when it hits dealers later this year and, at launch, it will only work with Blackberry and Android-powered devices running SYNC software. When it does arrive, the first three supported apps are Stitcher, Pandora (bye-bye XM/Sirius) and Orangatame’s OpenBeak Twitter program. More apps are sure to be available in the following months and Ford has setup a developer channel on SYNCMyRide to get programmers going.

For those of you currently rolling in a SYNC-equipped Ford or Lincoln, AppLink will be available as a download sometime next year, and for all you Apple fanboys, fear not, iPhone integration is on the way. Make the jump for all the details and a brace of videos showing off the technology.

[Source: Ford]

Continue reading 2011 Ford Fiesta to include AppLink, voice-control Blackberry and Android apps [w/videos]

2011 Ford Fiesta to include AppLink, voice-control Blackberry and Android apps [w/videos] originally appeared on Autoblog on Tue, 20 Apr 2010 00:01:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

TROY, N.Y., April 20 /CHICAGOPRESSRELEASE.COM/ — The Kaleel Jamison Consulting Group, Inc. (KJCG), has been named one of Consulting magazine’s Seven Small Jewels for 2010. The Seven Small Jewels are the gems of the consulting profession. Each year, Consulting magazine identifies seven growing firms with fewer than 200 billable consultants who are helping reshape and redefine the profession with new and innovative business models, technologies and practices. The Kaleel Jamison Consulting Group was selected from among 80 applicants for this year’s award.

“We are honored and excited to have received this award,” said Fred Miller, CEO and Chief Client Strategist with the firm. “During our 40-year history, The Kaleel Jamison Consulting Group has always continued to grow and refine our learning to stay relevant for our clients.”

“The Seven Small Jewels continue to defy the odds,” says Joe Kornik, Editor in Chief of Consulting magazine. “With fewer resources, fewer clients, fewer consultants and far fewer dollars on their balance sheets, they managed to not only survive–but thrive–in an economy that hindered many of the best firms of the profession.”

The Kaleel Jamison Consulting Group, Inc. uses Inclusion as the HOW(SM) to create organizations that inspire collaboration, innovation and breakthrough ideas for higher performance. They do this though crisis intervention and rapid deployment into organizations that results in tangible impact within 6 months and a sustainable culture change within 1-2 years.

http://www.consultingmag.com/article/ART647372?C=zHg81bVhsiWQiFBp

SOURCE The Kaleel Jamison Consulting Group, Inc.

http://www.kjcg.com

Distributed via Chicago Press Release Services